Shortness of Breath in Patients with Progressive Fibrous Interstitial Lung Disease Associated with Cardio Ischemia

Aleksandr Medvedev, А.ф. Абубикиров, Анна Сергеевна Зайцева, Л.а. Мазаева, Natalia Makaryants, Е. И. Шмелев, E.i. ShmelevDoctor 2021 · DOI

Abstract

Study Objective: To compare the quantitative aspects of shortness of breath in patients with fibrous interstitial lung disease (ILD) associated with cardio ischemia and to analyze functional and instrumental examination data.

Methods: An open comparative study of 47 patients with fibrous ILD (8 idiopathic pulmonary fibrosis, 25 chronic hypersensitive pneumonitis, 14 fibrous non-specific interstitial pneumonia). Patients were divided into a study group (n=24, ILD + cardio ischemia) and a control group (n=23, ILD only).

Results: Patients with comorbid cardio ischemia experienced significantly faster worsening of dyspnea (3.15 vs. 7.29 days, p < 0.05) and more intense respiratory symptoms. Functional testing revealed mixed restrictive and obstructive patterns and significantly reduced diffusing capacity in the study group. Exercise tolerance was lower, with marked desaturation (8.31% vs. 2.12% drop in $SpO_2$, p < 0.05).

Conclusion: In ILD patients, rapid intensification of shortness of breath often indicates underlying cardiac events. Standardized scales (Borg, MRC, CRP) are essential for differential diagnosis in primary care.

Introduction

Interstitial lung diseases (ILDs) are characterized by progressive pulmonary fibrosis, leading to chronic respiratory failure and debilitating dyspnea. However, the clinical picture is often complicated by comorbidities, particularly ischemic heart disease (IHD), which affects nearly half of this patient population.

Differentiating whether worsening breathlessness stems from pulmonary progression or a new cardiac event remains a significant diagnostic challenge. This study quantifies the impact of cardio ischemia on the clinical and functional status of ILD patients to aid in differential diagnosis and improve clinical management.

Methods

The study cohort consisted of 47 patients with various fibrous ILDs treated at the Central Scientific and Research Institute of Tuberculosis and City Clinical Hospital No. 24 in Moscow. They were categorized into two groups:

  1. Study Group (n=24): Fibrous ILD with confirmed cardio ischemia.
  2. Control Group (n=23): Isolated fibrous ILD without cardiac pathology.

Assessments included clinical scales (Borg, MRC, and CRP), physiological testing (spirometry, body plethysmography, and DLCO), exercise tolerance (6-minute walking test with continuous pulse oximetry), and imaging (high-resolution CT and Echocardiography).

Results

The presence of cardio ischemia significantly altered the clinical presentation and functional capacity of patients with ILD.

Clinical Characteristics and Symptom Tempo

The most critical finding was the "tempo" of symptom progression. Patients with comorbid IHD reported a significant worsening of dyspnea over a median of 3.15 days, whereas those with isolated ILD experienced a more gradual decline over 7.29 days. This rapid onset suggests that acute or subacute cardiac dysfunction often precipitates respiratory distress in these patients.

Table 1: Clinical characteristics and symptom intensity in patients with fibrous ILD with and without cardio ischemia.

Functional and Physiological Impact

While ILD typically presents as a restrictive lung disease, the study group exhibited mixed functional changes. Reductions in $FEV_1$ and instantaneous exhalation rates ($MCB_{25}$) indicated an obstructive component, likely due to perivascular edema from cardiac insufficiency narrowing the small airways. Furthermore, the study group showed a statistically significant reduction in diffusing capacity ($p < 0.05$).

Exercise tolerance was markedly lower in the study group. During the 6-minute walk test (6MWT), these patients covered less distance and experienced severe oxygen desaturation—an average $SpO_2$ drop of 8.31% compared to only 2.12% in the control group ($p < 0.05$).

Imaging and Cardiac Structure

CT scans showed similar levels of interstitial fibrosis in both groups. However, "ground glass" opacities were significantly more prevalent in the study group ($p < 0.05$), suggesting active inflammation or pulmonary congestion related to heart failure. Echocardiography confirmed that left ventricular hypertrophy and dysfunction were exclusive to the study group, whereas right-heart strain was common to both.

Discussion and Conclusion

The study highlights that in patients with fibrous ILD, the sudden intensification of shortness of breath is a red flag for cardiac complications, such as coronary events, heart failure, or arrhythmias. The "double whammy" of restrictive lung disease and cardiac ischemia leads to more severe desaturation and a mixed obstructive-restrictive physiological profile.

Clinicians should utilize standardized tools like the Borg and MRC scales alongside pulse oximetry during exercise to differentiate the drivers of dyspnea. Early identification of cardiac involvement is crucial for developing appropriate management algorithms and improving patient outcomes in primary care settings.

Summary updated

Abstract

Study Objective: To compare the quantitative aspects of shortness of breath in patients with fibrous interstitial lung disease (ILD) associated with cardio ischemia; to compare analysis results of the data obtained during functional and instrumental examinations. Study Design: Open comparative study in parallel groups. Materials and Methods. The study included 47 patients with fibrous ILD: 8 patients had idiopathic pulmonary fibrosis; 25 patients had chronic hypersensitive pneumonitis, and 14 patients had fibrous non-specific interstitial pneumonia. The patients were divided into two groups: study group of 24 patients with fibrous ILD associated with cardio ischemia, and 23 controls with fibrous ILD without cardio ischemia. We analysed clinical symptoms, instrumental examination results, changes in patients’ functional status with and without cardiac pathology. Study Results. In patients with fibrous ILD and cardio ischemia, respiratory symptoms were more intensive than in patients without cardio ischemia. Patients with fibrous ILD and cardio ischemia experienced worsening of their shortness of breath statistically earlier (in 3.15 days) vs patients with isolated fibrous ILD, who had shortness of breath in 7.29 days (p &lt; 0.05). Patients with fibrous ILD and cardio ischemia demonstrated mixed functional changes: restrictive (reduced lung capacity and FVRC) and obstructive disorders (reduced FEV1 and instantaneous exhalation rate, МСВ25); statistically significant reduction in diffusing lung capacity, p &lt; 0.05. A shorter 6-minute walking distance, more marked desaturation (SрO2 reduction by 8.31% in the study group and by 2.12% in controls, p &lt; 0.05), higher scores of Borg Dyspnoea Scale and CRP scale (Clinical, Radiographic, and Physiologic scoring system) demonstrated statistically reduced tolerance to physical exercises in patients with cardio ischemia. CT scans did not reveal any differences in the intensity of interstitial changes in patients of both groups; “ground glass” areas were significantly more intense in patients with cardio ischemia, p &lt; 0.05. Pulmonary hypertension and structural changes in right compartments of heart were recorded in patients in both groups; however, left ventricular hypertrophy and dysfunction were noted only in patients with cardio ischemia. Conclusion. In patients with fibrous ILD associated with cardio ischemia, intensification of shortness of breath can be a sign of a progressive respiratory disease or a new event: coronary event, atrial fibrillation attack, cardiac failure, chronic cor pulmonale. Assessment of the functional status using Borg Dyspnoea Scale, CRP, Medical Research Council Scale is a tool to identify the reasons of dyspnoea in primary care settings, to develop an algorithm for instrumental differential diagnosis of shortness of breath. Keywords: progressive fibrous interstitial lung diseases, quantification of shortness of breath, cardio ischemia.
BibTeX
@inproceedings{medvedev2021shortness,
  author = {Aleksandr Medvedev and А.Ф. Абубикиров and Анна Сергеевна Зайцева and Л.А. Мазаева and Natalia Makaryants and Е. И. Шмелев and E.I. Shmelev},
  title = {{Shortness of Breath in Patients with Progressive Fibrous Interstitial Lung Disease Associated with Cardio Ischemia}},
  booktitle = {Doctor},
  year = {2021},
  doi = {10.31550/1727-2378-2021-20-7-58-65},
}
Figure